FUNCTIONAL condition of vascular endothelial, subclinical manifestations of atherosclerosis in PATIENTS WITH articular syndrome caused by systemic connective tissue diseases, and perhaps of their CORRECTION BY APPLICATION L-arginine
Kuryata O.V.1, Mitrokhina O.S.2, Lysunets T.K. 3, Tarnavska N.M.3
Summary. Summary. The purpose of the study — to assess the condition of vascular endothelial function, subclinical manifestations of atherosclerosis in patients with articular syndrome caused by systemic connective tissue diseases, and the possibility of their correction by use of L-arginine .
Methods: clinical examination, determination of endothelium-dependent vasodilation (EDVD) based on reactive hyperemia, the thickness of the intima-media thickness (IMT), C-reactive protein (CRP), the calculation of glomerular filtration rate. According to purpose, a study was conducted in two stages. In the first phase for the assessment of the function of vascular endothelium (EDVD), subclinical manifestations of atherosclerosis (IMT) were examined in 100 patients (93 (93%) women and 7 (7%) males) with systemic connective tissue diseases between the ages of 18 to 55 years (mean — 48,73±1,25 years). Duration of the disease ranged from 1 to 468 months (mean — 88,85±9,12 months). The second stage of the study was to evaluate the efficacy of L-arginine (Tivortin® «Yuri Farm») in the correction of endothelial function in addition to the basic treatment in patients with systemic connective tissue diseases.
Conclusions. Among patients with articular syndrome caused by systemic connective tissue diseases showed a reduction in vascular endothelial function (76%) and subclinical manifestations of atherosclerosis (31%). It should be noted that the figures EDVD and IMT in patients with systemic lupus erythematosus in the normal range and were significantly different as compared with the patients with rheumatoid arthritis and systemic sclerosis (p<0,05). Application of L-arginine with basic therapy improves the condition of the vascular wall and is safe to use in patients with systemic connective tissue diseases.